In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
Stephen S WhiteheadAnna P DurbinKristen K PierceDan ElwoodBenjamin D McElvanyEllen A FraserMarya P CarmolliCecilia M TiberyNoreen A HynesMatthew JoJanece M LovchikCatherine J LarssonElena A DotyDorothy M DicksonCatherine J LukeKanta SubbaraoSean A DiehlBeth D KirkpatrickPublished in: PLoS neglected tropical diseases (2017)
ClinicalTrials.gov NCT01506570.
Keyphrases